NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CAI

Caris Life Sciences Inc

Jul 14 • 04:00PM ET

27.72

Dollar change +1.21
Percentage change 4.56	%

Healthcare • Biotechnology • USA • NASD

Held by: ONEQ ARKG TMSL TMED HELX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.43	Insider Own	48.50%	Shs Outstand	277.93M	Perf Week	4.49%
Market Cap	7.70B	Forward P/E	-	EPS next Y	-	Insider Trans	0.03%	Shs Float	121.38M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	2.30%	Short Float	1.12%	Perf Quarter	-
Income	-371.20M	P/S	17.03	EPS this Y	19.50%	Inst Trans	49.80%	Short Ratio	0.71	Perf Half Y	-
Sales	452.50M	P/B	-	EPS next Y	-	ROA	-187.60%	Short Interest	1.36M	Perf YTD	-1.00%
Book/sh	-73.78	P/C	230.67	EPS next 5Y	-	ROE	21.00%	52W High	30.70 -9.71%	Perf Year	-
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	25.40 9.13%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	46.70%	Volatility	3.67% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-49.20%	ATR (14)	1.51	Perf 10Y	-
Dividend Ex-Date	Sep 09, 2021	Quick Ratio	0.70	Sales Y/Y TTM	-	Profit Margin	-60.40%	RSI (14)	49.50	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	1.10	EPS Q/Q	-	SMA20	3.28%	Beta	-	Target Price	-
Payout	0.00%	Debt/Eq	-	Sales Q/Q	49.90%	SMA50	3.28%	Rel Volume	0.29	Prev Close	26.51
Employees	1769	LT Debt/Eq	-	Earnings	May 28	SMA200	3.28%	Avg Volume	1.92M	Price	27.72
IPO	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	573,059	Change	4.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Initiated	Wolfe Research	Outperform	$32
Jul-14-25	Initiated	TD Cowen	Buy	$32
Jul-14-25	Initiated	JP Morgan	Overweight	$31
Jul-14-25	Initiated	Guggenheim	Buy	$32
Jul-14-25	Initiated	Evercore ISI	Outperform	$33
Jul-14-25	Initiated	Citigroup	Buy	$34
Jul-14-25	Initiated	BTIG Research	Buy	$38
Jul-14-25	Initiated	BofA Securities	Buy	$31

Jul-08-25 06:30AM	Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection (PR Newswire)
Jun-20-25 05:01AM	Caris Life Sciences indicated to open at $30, IPO priced at $21 per share (TipRanks)
Jun-18-25 02:50PM	This 'AI TechBio' company goes public as IPO demand spreads to biotech (MarketWatch)
01:37PM	The IPO Market Extends Its Comeback (Barrons.com)

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Spetzler David Baxley	President	Jun 20 '25	Option Exercise	2.44	75,000	183,000	558,668	Jun 23 06:41 PM
Denton John Russel	See Remarks	Jun 20 '25	Buy	21.00	7,500	157,500	123,591	Jun 23 06:34 PM
Brille Brian J	See Remarks	Jun 20 '25	Buy	21.00	30,000	630,000	162,428	Jun 23 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAI

Caris Life Sciences Inc

Upgrade your FINVIZ experience